Jardiance and Testosterone Interaction

Pharmacokinetic Profile: Why No Direct Drug-Drug Interaction Exists

Empagliflozin is metabolized primarily through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9, with minimal CYP450 involvement [1]. The drug is also a substrate of P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/1B3, but neither pathway overlaps with testosterone metabolism.

Testosterone undergoes hepatic oxidation via CYP3A4 and, to a lesser extent, CYP2C9 and CYP2C19 [2]. It does not inhibit or induce UGT enzymes. Because the two drugs occupy entirely different metabolic lanes, coadministration does not alter the area under the curve (AUC) or peak plasma concentration (Cmax) of either agent. The FDA label for empagliflozin lists no interaction with androgens, and the testosterone cypionate prescribing information does not flag SGLT2 inhibitors [3]. This means dose adjustments based on pharmacokinetics alone are not required.

The Hematocrit Overlap: A Pharmacodynamic Concern Worth Tracking

Both agents raise hematocrit through independent mechanisms, and this is the primary reason clinicians should monitor patients receiving the combination.

Testosterone stimulates erythropoiesis directly by increasing renal erythropoietin production and suppressing hepcidin, the master iron-regulatory hormone [4]. A meta-analysis of 15 randomized trials (N=3,014) published in The Lancet Healthy Longevity found that testosterone therapy increased hemoglobin by a mean of 1.02 g/dL and hematocrit by 3.2 percentage points compared to placebo [5]. Polycythemia (hematocrit >54%) occurred in 5-14% of men on standard TRT doses across the Testosterone Trials (TTrials, N=790) [6].

Empagliflozin raises hematocrit through a different route. SGLT2 inhibition produces osmotic diuresis and natriuresis, contracting plasma volume by approximately 7% within the first weeks of therapy [7]. The EMPA-REG OUTCOME trial (N=7,020) documented a mean hematocrit increase of 2.8 percentage points from baseline in the empagliflozin 25 mg arm over 12 weeks [8]. This effect is hemoconcentration rather than true erythrocytosis, but clinically the result is the same: a higher measured hematocrit value.

When a patient takes both drugs, these effects are additive. A man starting with a baseline hematocrit of 47% could plausibly reach 52-54% within 3-6 months of combined therapy. The Endocrine Society's 2018 TRT guideline recommends holding testosterone if hematocrit exceeds 54% and resuming at a lower dose after therapeutic phlebotomy [9].

Lipid Effects: A Secondary Consideration

Testosterone replacement typically reduces HDL cholesterol by 5-15% and may modestly lower total cholesterol [10]. The magnitude depends on the formulation and route of administration. Transdermal testosterone produces smaller HDL reductions than intramuscular injections.

Empagliflozin has a neutral-to-mildly-favorable lipid profile. In EMPA-REG OUTCOME, LDL rose by approximately 4 mg/dL, but cardiovascular outcomes improved regardless, driven by hemodynamic rather than lipid mechanisms [8]. The combination does not produce a clinically dangerous lipid pattern, but clinicians treating men with pre-existing dyslipidemia or cardiovascular disease should obtain a fasting lipid panel at baseline and 6 months into combined therapy.

Glycemic and Metabolic Interactions

Testosterone replacement improves insulin sensitivity. A randomized trial by Dhindsa et al. (N=94) published in Diabetes Care demonstrated that testosterone therapy in hypogonadal men with type 2 diabetes reduced HOMA-IR by 15.2% over 24 weeks [11]. This effect may potentiate the glucose-lowering action of empagliflozin.

For most patients this is beneficial. Empagliflozin lowers HbA1c by 0.7-0.8% as monotherapy [1], and the added insulin-sensitizing effect of testosterone could push patients into tighter glycemic control without hypoglycemia risk (since neither drug stimulates insulin secretion). Clinicians should anticipate a possible need to down-titrate sulfonylureas or insulin if these are also prescribed. Empagliflozin itself carries low hypoglycemia risk as it works independently of the beta-cell.

Cardiovascular Safety Data for the Combination

Empagliflozin has strong cardiovascular outcome data. EMPA-REG OUTCOME showed a 38% relative risk reduction in cardiovascular death (HR 0.62 to 95% CI 0.49-0.77, P<0.001) [8]. EMPEROR-Preserved (N=5,988) and EMPEROR-Reduced (N=3,730) extended the benefit to heart failure populations regardless of diabetes status [12].

Testosterone's cardiovascular profile is more complex. The TRAVERSE trial (N=5,246), the first large cardiovascular safety trial of testosterone, reported non-inferiority for major adverse cardiovascular events (MACE HR 0.99 to 95% CI 0.81-1.21) but found a signal for increased atrial fibrillation and acute kidney injury in the treatment arm [13]. Polycythemia-driven thrombotic risk remains the primary concern.

No dedicated trial has studied the combination. The best available inference: empagliflozin's diuretic-like effects and proven cardiovascular benefit may partially offset the rheological risk from testosterone-induced erythrocytosis by reducing preload and congestion. This remains speculative. Clinicians should not assume cardioprotection from empagliflozin negates the need for hematocrit surveillance.

Monitoring Protocol for Combined Use

"For patients on both testosterone and an SGLT2 inhibitor, I check hematocrit at baseline, 3 months, and 6 months, then every 6 to 12 months if stable," notes the Endocrine Society clinical practice guideline for testosterone therapy [9].

A practical monitoring schedule:

Baseline (before starting the second agent): CBC with differential, comprehensive metabolic panel (CMP) including creatinine and eGFR, fasting lipids, HbA1c, total and free testosterone.

Week 4-6: Basic metabolic panel to assess volume status and electrolytes (SGLT2 inhibitors can cause hypovolemia and mild hyperkalemia in CKD).

Month 3: CBC (hematocrit is the critical value), CMP, PSA if clinically indicated.

Month 6: Full panel repeat including lipids, HbA1c, testosterone trough level.

Ongoing: CBC every 6 months if hematocrit remains below 50%. If hematocrit is 50-54%, increase frequency to every 3 months and consider testosterone dose reduction or switching from intramuscular to transdermal formulation.

Dose Adjustment Considerations

No pharmacokinetic dose adjustment is needed. Pharmacodynamic dose adjustments center on hematocrit management:

If hematocrit exceeds 54%, the Endocrine Society guideline recommends stopping testosterone, performing therapeutic phlebotomy to target hematocrit below 50%, and restarting at a lower dose [9]. Empagliflozin does not need to be held in this scenario since its contribution is hemoconcentration (reversible with rehydration) rather than true polycythemia.

If a patient experiences volume depletion symptoms (orthostatic hypotension, dizziness, elevated creatinine) while on empagliflozin plus testosterone, consider whether the testosterone-induced increase in muscle mass and metabolic rate is increasing insensible fluid losses. Counsel the patient to increase fluid intake by 500-750 mL/day, and reassess empagliflozin dosing (10 mg vs. 25 mg) if symptoms persist.

Renal Considerations

Empagliflozin provides renal protection. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in kidney disease progression (HR 0.72 to 95% CI 0.64-0.82) [14]. This benefit extends to patients with eGFR as low as 20 mL/min/1.73m².

Testosterone does not have a direct nephrotoxic effect, but polycythemia can impair renal microvascular flow. The TRAVERSE trial flagged a modest increase in acute kidney injury events in the testosterone arm [13]. For men with CKD stages 3-4, the combination demands tighter hematocrit targets. Consider therapeutic phlebotomy at hematocrit of 52% rather than waiting for 54%.

Patient Counseling Points

Patients should understand three things about taking these medications together. First, there is no pill-timing interaction. Empagliflozin can be taken at any time relative to testosterone injections or gel application. Second, adequate hydration becomes more important when combining an osmotic diuretic (empagliflozin) with a drug that increases red cell mass (testosterone). Aim for at least 2.5 liters of total daily fluid. Third, symptoms of thick blood (headache behind the eyes, facial flushing, vision changes, fingertip tingling) warrant urgent lab evaluation and should not be dismissed.

"The Endocrine Society recommends measuring hematocrit 3 to 6 months after starting testosterone and periodically thereafter, with a threshold of 54% prompting intervention," states the 2018 guideline document [9].

Special Populations

Men with heart failure: Empagliflozin is FDA-approved for HFrEF and HFpEF. Testosterone use in heart failure is more nuanced. Small trials suggest testosterone improves functional capacity (6-minute walk distance) in men with HFrEF [15], but larger safety data are lacking. The combination may be reasonable in euvolemic, stable HF patients with confirmed hypogonadism, but requires cardiology co-management.

Men over 65: Age-related decline in renal function and higher baseline hematocrit narrow the safety margin. Start with empagliflozin 10 mg (not 25 mg) and testosterone at the lowest effective dose. Monitor volume status aggressively in the first 8 weeks.

Men on anticoagulation: Polycythemia increases thrombotic risk independently of coagulation factor activity. If a patient takes warfarin or a DOAC alongside both agents, hematocrit targets should be more conservative (hold testosterone at 52% rather than 54%).